XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Warrants (Tables)
12 Months Ended
Dec. 31, 2018
Warrants  
Schedule of warrants outstanding and warrant activity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance

 

 

 

 

 

 

 

Balance

 

 

 

 

Exercise

 

Expiration

 

December 31, 

 

Warrants

 

Warrants

 

Warrants

 

December 31, 

Description

    

Classification

    

Price

    

Date

    

2017

    

Issued

    

Exercised

    

Expired

    

2018

Non-tradable warrants

 

Liability

 

$

172.50

 

July 2021

 

6,456

 

 —

 

 —

 

 —

 

6,456

Tradable warrants

 

Liability

 

$

73.80

 

July 2021

 

212,801

 

 —

 

 —

 

 —

 

212,801

Non-tradable pre-funded warrants

 

Equity

 

$

0.15

 

July 2023

 

394

 

 —

 

 —

 

 —

 

394

Non-tradable warrants

 

Equity

 

$

6.69375

 

*

 

 —

 

663,167

 

 —

 

 —

 

663,167

Non-tradable warrants

 

Equity

 

$

7.96875

 

*

 

 —

 

33,158

 

 —

 

 —

 

33,158

Non-tradable warrants

 

Equity

 

$

14.10

 

March 2021

 

 —

 

5,000

 

 —

 

 —

 

5,000

Non-tradable warrants

 

Equity

 

$

21.15

 

March 2021

 

 —

 

8,333

 

 —

 

 —

 

8,333

Non-tradable warrants

 

Equity

 

$

7.7895

 

June 2021

 

 —

 

15,000

 

 —

 

 —

 

15,000

Non-tradable pre-funded warrants

 

Equity

 

$

0.15

 

none

 

 —

 

196,167

 

(110,000)

 

 —

 

86,167

Non-tradable warrants

 

Equity

 

$

6.375

 

**

 

 —

 

4,509,804

 

(76,842)

 

 —

 

4,432,962

Non-tradable pre-funded warrants

 

Equity

 

$

0.15

 

none

 

 —

 

815,686

 

(553,618)

 

 —

 

262,068

 

 

 

 

 

 

 

 

 

219,651

 

6,246,315

 

(740,460)

 

 —

 

5,725,506


*     These preferred stock warrants expire on the earlier of (A) the one-month anniversary of the date on which the Company publically releases topline results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician’s Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. These preferred stock warrants may be exercised on a cashless basis in certain circumstances specified therein.

**   These preferred stock warrants expire on the 18-month anniversary of June 8, 2018, the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Certificate of Amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000, was filed with the Secretary of State of the State of Delaware. These preferred stock warrants may be exercised on a cashless basis in certain circumstances specified therein.